Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BioAge Labs, Inc. (BIOA)

BioAge Labs Q3 net loss widens to $33.5 million on higher BGE-102 trial costs

Negative Impact 3 of 5 earnings Written later

BioAge Labs reported third quarter 2026 results on November 5, 2026. Collaboration revenue fell to $0.3 million from $2.1 million, and the net loss widened to $33.5 million, or $0.73 per share, from $20.2 million, or $0.56 per share, a year earlier, mainly due to clinical trial costs for BGE-102. The company had about $352.3 million in cash, cash equivalents and marketable securities, which it says will fund operations through 2029.

Key points

  • Net loss was $33.5 million ($0.73 per share) for the quarter ended September 30, 2026, versus $20.2 million ($0.56 per share) a year earlier.
  • Research and development expenses rose to $30.2 million from $18.5 million, driven by a $13.2 million increase in BGE-102 direct costs tied to the QUELL-CV and QUELL-DME trials.
  • Collaboration revenue was $0.3 million, down from $2.1 million, mainly due to a $1.7 million cumulative catch-up adjustment tied to a September 2026 Novartis agreement amendment.
  • Cash, cash equivalents and marketable securities totaled about $352.3 million as of September 30, 2026; QUELL-CV topline data are expected in the fourth quarter of 2026.

The filing

CompanyBioAge Labs, Inc. (BIOA)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:35 PM ET
Accession number0001193125-26-450008

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.